| Literature DB >> 29221895 |
Justin R Ortiz1, Julian Hickling2, Rebecca Jones3, Armen Donabedian4, Othmar G Engelhardt5, Jacqueline M Katz6, Shabir A Madhi7, Kathleen M Neuzil8, Guus F Rimmelzwaan9, James Southern10, David J Spiro11, Joachim Hombach12.
Abstract
In August 2016, the World Health Organization (WHO) convened the "Eighth meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses" to discuss the regulatory requirements and pathways for licensure of next-generation influenza vaccines, and to identify areas where WHO can promote the development of such vaccines. Participants included approximately 120 representatives of academia, the vaccine industry, research and development funders, and regulatory and public health agencies. They reviewed the draft WHO preferred product characteristics (PPCs) of vaccines that could address prioritized unmet public health needs and discussed the challenges facing the development of such vaccines, especially for low- and middle-income countries (LMIC). They defined the data desired by public-health decision makers globally and explored how to support the progression of promising candidates into late-stage clinical trials and for all countries. This report highlights the major discussions of the meeting.Entities:
Keywords: Influenza; Nextgeneration influenza vaccine; Pandemic influenza vaccine; Seasonal influenza vaccine; Universal influenza vaccine; Vaccine development
Mesh:
Substances:
Year: 2017 PMID: 29221895 DOI: 10.1016/j.vaccine.2017.11.061
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641